Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Apr;79(11-12):1665–1671. doi: 10.1038/sj.bjc.6690266

In vitro assessment of Lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines

R A M Al-Mufti 1, R B Pedley 2, D Marshall 2, R H J Begent 2, A Hilson 3, M C Winslet 1, K E F Hobbs 1
PMCID: PMC2362812  PMID: 10206275

Abstract

Intra-arterial Lipiodol has been used to deliver targeted therapies to primary, and some metastatic, liver cancers. Targeted radiotherapy has been used by substituting the iodine in Lipiodol with 131Iodine (131I). Early clinical results are encouraging, but the variable response may partly depend on local pharmacokinetics. This study evaluated the in vitro cytotoxic effects of 131I-Lipiodol on human hepatocellular carcinoma (Hep-G2), human colorectal metastatic cancer (SW620), human colorectal hepatic cancer (LoVo) and human umbilical vein endothelial cells (HUVEC) cell lines. The cell cultures were exposed to 131I-Lipiodol for 48 h, following which cell counts and viability were assessed by haemocytometer, S-Rhodamine uptake and radioactivity assay. The effect of exposure to control Lipiodol, 131I-Lipiodol and 131I alone was evaluated. 131I-Lipiodol was cytotoxic against all the cancer cell lines but not against the non-malignant (HUVEC) cell line. The cytotoxicity effects were very similar in all the cancer cell lines. There were no cytotoxic effects following exposure to plain 131I in any of the cell lines (malignant and non-malignant). A similar trend was seen with radioactivity counts using a gamma counter. The cytotoxic effect of 131I-Lipiodol had a graded effect with an increase in cytotoxicity following the increase in the radioactive dose. This study showed that there was a marked cytotoxic effect by 131I-Lipiodol on all the cancer cell lines. There was no difference between the controls and the 131Iodine. This suggests that effective 131I-Lipiodol targeted therapy is dependent on the uptake and retention of Lipiodol by malignant cells. © 1999 Cancer Research Campaign

Keywords: Lipiodol therapy, targeted radiotherapy, primary liver cancer, colorectal liver metastases, in-vitro cytotoxicity

Full Text

The Full Text of this article is available as a PDF (333.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bhattacharya S., Dhillon A. P., Winslet M. C., Davidson B. R., Shukla N., Gupta S. D., Al-Mufti R., Hobbs K. E. Human liver cancer cells and endothelial cells incorporate iodised oil. Br J Cancer. 1996 Apr;73(7):877–881. doi: 10.1038/bjc.1996.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bretagne J. F., Raoul J. L., Bourguet P., Duvauferrier R., Deugnier Y., Faroux R., Ramée A., Herry J. Y., Gastard J. Hepatic artery injection of I-131-labeled lipiodol. Part II. Preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases. Radiology. 1988 Aug;168(2):547–550. doi: 10.1148/radiology.168.2.2839867. [DOI] [PubMed] [Google Scholar]
  3. Chou F. I., Lui W. Y., Chi C. W., Chan W. K. I-131-lipiodol cytotoxicity in hepatoma cells. Proc Natl Sci Counc Repub China B. 1994 Oct;18(4):154–160. [PubMed] [Google Scholar]
  4. Drewinko B., Romsdahl M. M., Yang L. Y., Ahearn M. J., Trujillo J. M. Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res. 1976 Feb;36(2 Pt 1):467–475. [PubMed] [Google Scholar]
  5. Friedman M. A. Primary hepatocellular cancer--present results and future prospects. Int J Radiat Oncol Biol Phys. 1983 Dec;9(12):1841–1850. doi: 10.1016/0360-3016(83)90352-8. [DOI] [PubMed] [Google Scholar]
  6. Jaffe E. A. Cell biology of endothelial cells. Hum Pathol. 1987 Mar;18(3):234–239. doi: 10.1016/s0046-8177(87)80005-9. [DOI] [PubMed] [Google Scholar]
  7. Jaffe E. A., Nachman R. L., Becker C. G., Minick C. R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973 Nov;52(11):2745–2756. doi: 10.1172/JCI107470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Knowles B. B., Howe C. C., Aden D. P. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science. 1980 Jul 25;209(4455):497–499. doi: 10.1126/science.6248960. [DOI] [PubMed] [Google Scholar]
  9. Konno T., Maeda H., Iwai K., Maki S., Tashiro S., Uchida M., Miyauchi Y. Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer. 1984 Dec 1;54(11):2367–2374. doi: 10.1002/1097-0142(19841201)54:11<2367::aid-cncr2820541111>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  10. Konno T., Maeda H., Iwai K., Tashiro S., Maki S., Morinaga T., Mochinaga M., Hiraoka T., Yokoyama I. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol. 1983 Aug;19(8):1053–1065. doi: 10.1016/0277-5379(83)90028-7. [DOI] [PubMed] [Google Scholar]
  11. Leibovitz A., Stinson J. C., McCombs W. B., 3rd, McCoy C. E., Mazur K. C., Mabry N. D. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 1976 Dec;36(12):4562–4569. [PubMed] [Google Scholar]
  12. Madden M. V., Krige J. E., Bailey S., Beningfield S. J., Geddes C., Werner I. D., Terblanche J. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut. 1993 Nov;34(11):1598–1600. doi: 10.1136/gut.34.11.1598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Nakakuma K., Tashiro S., Hiraoka T., Uemura K., Konno T., Miyauchi Y., Yokoyama I. Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer. 1983 Dec 15;52(12):2193–2200. doi: 10.1002/1097-0142(19831215)52:12<2193::aid-cncr2820521203>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  14. Novell R., Hilson A., Hobbs K. Ablation of recurrent primary liver cancer using 131I-lipiodol. Postgrad Med J. 1991 Apr;67(786):393–395. doi: 10.1136/pgmj.67.786.393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Raoul J. L., Bourguet P., Bretagne J. F., Duvauferrier R., Coornaert S., Darnault P., Ramée A., Herry J. Y., Gastard J. Hepatic artery injection of I-131-labeled lipiodol. Part I. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology. 1988 Aug;168(2):541–545. doi: 10.1148/radiology.168.2.2839866. [DOI] [PubMed] [Google Scholar]
  16. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4;82(13):1107–1112. doi: 10.1093/jnci/82.13.1107. [DOI] [PubMed] [Google Scholar]
  17. Vetter D., Wenger J. J., Bergier J. M., Doffoel M., Bockel R. Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western comparative study in 60 patients. Hepatology. 1991 Mar;13(3):427–433. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES